louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02829645: Evaluation of the Clinical, Neuropsychological and Psychosocial Situation of Patient With Eating Disorders.
Official title: Evaluation of the Clinical, Neuropsychological and Psychosocial Situation of Patient With Eating Disorders.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Eating Disorders
Keywords: eating disoders
neuropsychology
pronostic
Lead sponsor: University Hospital, Montpellier
Sponsor class: OTHER
First posted: 2016-07-12
Enrollment: 370
Sex: ALL
Minimum age (years): 15
Maximum age (years): 65
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP

Brief summary: Eating disorders (ED) are serious mental illnesses with an excess mortality and many affects in the quality of life of patients and thier relatives. Management of ED is very difficult : the prognosis remains relatively poor both in terms of remission rate and quality of life. In this context, the contribution of new strategies for pathophysiological exploration and the development of therapeutic options are crucial.

In this project the investigators aim to constitute un cohort of patients from a day unit specialized in the management of ED. A prospective follow-up will be offered to patients to assess their clinical and psycho-social evolution. The overall objective is to identify which factors are prognostic of clinical improvement of the ED. We also want to better characterize patients that will migrate from diagnosis to another.

Detailed description: The investigators propose to assess, with a cohort of patients with ED the prognostic value of cognitive abnormalities associated with ED (cognitive flexibility and central coherence) They will recruit 370 patients suffering from a current ED (anorexia, bulimia, binge eating disorder, Eating disorder not otherwise specified).

Each patient will be reassessed every year for 3 years.

Eligibility criteria: Inclusion criteria:

* respond to DSM 4 criteria for ED
* Age 15 to 65 years
* Signing an informed consent.
* Affiliated to a social security scheme or being the beneficiary of such a scheme.

Exclusion criteria:

* Manifest inability of the subject to understand / perform clinical and neuropsychological evaluations and tasks
* Major protected by law (guardianship)
* Privation of liberty by judicial or administrative decision
* Pregnant or lactating women

Primary outcomes:
measure: Frequency of remission rates
timeFrame: At the inclusion and at 12, 24 and 36 months
Secondary outcomes:
measure: score to another neuropsychological test (Iowa gambling task (IGT)
timeFrame: At the inclusion and at 12, 24 and 36 months
measure: scores to another other neuropsychological test : Rey-Osterrieth complex figure
timeFrame: At the inclusion and at 12, 24 and 36 months
measure: scores to another neuropsychological test : D2 test of attention
timeFrame: At the inclusion and at 12, 24 and 36 months
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06188845: Kinesio Taping in Stroke Patient
Official title: Improved Hand Function in High-functioning Stroke Survivors by Applying Kinesio Taping: A Prospective Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Stroke
Cardiovascular Diseases
Physical Disability
Keywords: kinesio tape
high-functioning stroke
hand function
stroke
Lead sponsor: Taiwan Municipal An-Nan Hospital-China Medical University
Sponsor class: OTHER
First posted: 2024-01-03
Enrollment: 17
Sex: ALL
Minimum age (years): 32
Maximum age (years): 77
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Despite being nearly independent in daily life, chronic high-functioning stroke survivors still experienced mild impairments in skilled hand function. Kinesio Taping (KT) has been used to help stroke patients improve their balance and ambulation. Few studies explored the effects of KT on fine motor function in stroke patients. The purpose of this study was to investigate the hand function performance of high-functioning stroke survivors after KT. Participants were divided into two groups: KT group and control group. Last two days, the KT group received KT intervention. After the taping was removed, baseline and post-test evaluation were conducted. Outcome measures included muscle strength, range of motion (ROM), spasticity, fine motor function, and self-reported upper limb disability. The results revealed that the KT group had less spasticity, increasing ROM trend, and improved fine motor function and disability. KT improved spasticity, active movement, and muscle flexibility, resulting in more skilled and delicate hand function in chronic high-functioning stroke survivors.


Eligibility criteria: Inclusion Criteria:

* (1) Stroke with unilateral hemiparesis, (2) onset duration \> 6 months, (3) Brunnstrom stage in the proximal and distal parts of the upper extremity \> stage III, and (4) adequate cognitive ability to understand and cooperate with the experiment procedure.

Exclusion Criteria:

* Participants with skin problem (such as allergies, open wound), a history of upper extremity musculoskeletal diseases (such as fractures, tendon ruptures), or other peripheral neurological or systemic diseases were excluded.

Primary outcomes:
measure: Muscle strength
timeFrame: Baseline and post-test( 2 days later)
measure: AROM and PROM
timeFrame: Baseline and post-test( 2 days later)
measure: Spasticity
timeFrame: Baseline and post-test( 2 days later)
measure: The Action Research Arm Test
timeFrame: Baseline and post-test( 2 days later)
measure: Quick DASH
timeFrame: Baseline and post-test( 2 days later))
Secondary outcomes:
Other outcomes:
Locations:
city: Tainan
country: Taiwan
facility: An Nan Hospital, China Medical University
Study officials:
affiliation: Department of Rehabilitation, An Nan Hospital, China Medical University, Tainan, Taiwan
name: Ya-Wen Tsai, MS
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00299845: Randomized Trial for Pharmacogenomics-based Proton Pump Inhibitor Therapy in Children
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE4
Conditions: Gastroesophageal Reflux
Keywords: gastroesophageal reflux
children
lansoprazole
cytochrome P450 2C19 (CYP2C19)
pharmacogenomics
genetic polymorphisms
individualized medicine
pharmacokinetics/dynamics
Lead sponsor: Osaka University
Sponsor class: OTHER
First posted: 2006-03-07
Enrollment: 0
Sex: ALL
Minimum age (years): 1
Maximum age (years): 15
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Proton pump inhibitors are administered to children as off-label use in Japan. The purpose of this study is to evaluate the effects of CYP2C19 genotypes on pharmacokinetic /pharmacodynamic profiles of PPI in children. The results will provide the beneficial information for the individualized medicine of PPI in children.


Eligibility criteria: Inclusion Criteria:

* Patients with gastroesophageal reflux
* The patient's parent or guardian gives written informed consent including pharmacogenomic analysis
* The patient is willing and able to give assent to participate.

Exclusion Criteria:

* Serious hepatic disease, pulmonary disease, renal disease and blood disorder
* Inadequate clinical conditions

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Suita
country: Japan
facility: Osaka University Hospital
state: Osaka
Study officials:
affiliation: Graduate School of Pharmaceutical Sciences, Osaka University
name: Junichi Azuma, MD
role: STUDY_CHAIR
References:
Clinical trial NCT03916445: Resilience and Quality of Life in Patients With Gynaecological Carcinomas and Chronic Gynaecological Diseases
Official title: Resilience and Quality of Life in Patients With Gynaecological Carcinomas and Chronic Gynaecological Diseases: A Pilot Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Gynecologic Disease
Gynecologic Cancer
Lead sponsor: University Hospital, Basel, Switzerland
Sponsor class: OTHER
First posted: 2019-04-16
Enrollment: 132
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: female patients with a chronic gynecological disease or a gynaecological carcinoma, currently treated at the hospital

Brief summary: The intended pilot project aims at evaluating the feasibility and acceptability of questionnaires about resilience and quality of life in two different patient groups (either with a gynaecological carcinoma ora chronic gynaecological disease). The results provided by this pilot study will build the basis of an upcoming, larger project including these questionnaires and the main objective of assessing resilience. More precisely, the study aims at answering the following questions. How is the overall resilience and quality of life in the target population at one assessment point? Are the instruments used in this pilot feasible for the target population when assessing resilience and quality of life?


Eligibility criteria: Inclusion Criteria:

* female,
* \>18 years old,
* german speaking

exclusion criteria:

- insufficient study language skills

Primary outcomes:
measure: resilience measured by questionnaire
timeFrame: up to 1 year
Secondary outcomes:
measure: quality of life measured by questionnaire
timeFrame: up to 1 year
Other outcomes:
measure: quality of life measured by VAS in the questionnaire
timeFrame: up to 1 year
Locations:
city: Basel
country: Switzerland
facility: Universitätsspital Frauenklinik
state: Basel-Stadt
Study officials:
affiliation: University Hospital, Basel, Switzerland
name: Viola Heinzelmann-Schwarz, Prof. Dr. MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00895947: Interferon Alpha Lozenges in the Prevention of Winter Colds and Flu
Official title: Evaluation of Natural Human Interferon Alpha Lozenges in the Prevention of Winter Colds and Flu in Perth, Western Australia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Upper Respiratory Tract Infections
Keywords: Prophylaxis
Treatment
Symptoms
Winter Colds and Flu
Lead sponsor: Ainos, Inc. (f/k/a Amarillo Biosciences Inc.
Sponsor class: INDUSTRY
Collaborators: name: Department of Health, Western Australia
First posted: 2009-05-08
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The aim of the study is to see if lozenges containing a low dose of interferon-alpha can prevent and/or reduce the severity of colds and flu. Starting about 1 month before the expected start of the winter colds and flu season in Perth, Australia, healthy volunteers will allow a lozenge containing interferon, or a lozenge containing no medicine (a placebo), to dissolve in their mouth once a day for 16 weeks. Blood tests at the start and end of treatment will determine whether interferon was able to prevent infections with cold/flu viruses. Once a week, volunteers will complete a survey about their cold/flu symptoms, medications taken, days of work missed, etc. to see if interferon was able to make their winter colds and flu less severe.


Eligibility criteria: Inclusion Criteria:

* Male or non-pregnant female
* Females of child-bearing potential must practice a medically accepted form of birth control

Exclusion Criteria:

* Currently exhibiting an acute upper respiratory tract infection
* history of chronic respiratory disease requiring regular therapy(i.e. COPD, asthma, bronchitis, etc.)
* any condition likely to increase the risk of severe or complicated influenza (i.e. cardiac disease, chronic renal disease, endocrine diseases, including diabetes and/or immunosuppressive therapy)
* any condition requiring regular treatment with antihistamines, analgesics or antipyretics
* known infection with HIV, hepatitis B virus or hepatitis C virus
* any other serious, uncontrolled disease
* any active infections requiring use of antibiotic or antiviral drugs
* non-ambulatory status
* suspected drug or alcohol abuse

Primary outcomes:
measure: Frequency of Influenza-like Illness
timeFrame: 16 weeks
Secondary outcomes:
measure: Symptom Incidence/Severity
timeFrame: 16 weeks
measure: Impact of Cold/Flu Symptoms
timeFrame: 16 weeks
measure: Negative Events Related to Cold/Flu Symptoms
timeFrame: 16 weeks
measure: Incidence/Severity of Viral Respiratory Infections
timeFrame: 16 weeks
Other outcomes:
Locations:
city: Nedlands
country: Australia
facility: University of Western Australia
state: Western Australia
Study officials:
affiliation: Path West Laboratory Medicine WA
name: David Smith, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06679647: Acceptability, Usability and Preliminary Effectiveness of ChatGPT in Increasing Seasonal Influenza Vaccination Uptake Among Older Adults in Hong Kong
Official title: Acceptability, Usability and Preliminary Effectiveness of ChatGPT in Increasing Seasonal Influenza Vaccination Uptake Among Older Adults in Hong Kong
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Behavior Change Interventions
Lead sponsor: Chinese University of Hong Kong
Sponsor class: OTHER
First posted: 2024-11-07
Enrollment: 50
Sex: ALL
Minimum age (years): 65
Standard ages: OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: In this project, we will train a ChatGPT to provide real-time answers to questions related to the SIV for older adults in Hong Kong.

This study aims to evaluate the usability, acceptability, and preliminary effectiveness of the ChatGPT among 50 community-living people aged 65 years and above in Hong Kong.

The primary objectives are to evaluate the usability and acceptability (including the extent of usage and subjective experiences of behavioural, cognitive, and affective engagement) of the ChatGPT at the end of the 4-week intervention period (T1).

The secondary objectives are to evaluate the following conditions measured at T1, as compared to those measured at baseline (T0):

1. Self-reported uptake of SIV in the past month.
2. Changes in behavioural intention to receive SIV for the approaching flu season.
3. Changes in knowledge and attitudes related to SIV.


Eligibility criteria: Inclusion Criteria:

* Aged ≥65 years;
* Possession of a Hong Kong ID;
* Able to speak and comprehend Cantonese;
* Have a smartphone with internet access;
* Have not taken SIV for the approaching flu season.

Exclusion Criteria:

* With diagnosis of cognitive impairment or dementia;
* Either blindness or deafness;
* With known contraindications to the SIV as indicated by the Hong Kong Centre for Health Protection

Primary outcomes:
measure: Perceived usability
timeFrame: 1 month
measure: Extent of usage documented by the ChatGPT
timeFrame: 1 month
measure: Subjective experiences related to behavioural, cognitive, and affective engagement
timeFrame: 1 month
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Chinese University of Hong Kong
name: Zixin Wang, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00674947: A Phase I Study of BIIB015 in Relapsed/Refractory Solid Tumors
Official title: A Phase I Study of BIIB015, a Humanized, IgG1, DM4-Conjugated, Anti-Cripto, Monoclonal Antibody, for the Treatment of Subjects With Relapsed or Refractory Solid Tumors
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Solid Tumors
Keywords: Relapsed
Refractory
Lead sponsor: Biogen
Sponsor class: INDUSTRY
First posted: 2008-05-08
Enrollment: 55
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Phase 1, open-labeled, safety and tolerability study for the treatment of subjects with relapsed or refractory solid tumors.


Eligibility criteria: Inclusion Criteria

* Age 18 years or older at the time of informed consent.
* Solid tumors that are relapsed or refractory to at least 1 prior anti-cancer systemic therapy and for which no standard therapy exists.
* ECOG Performance Status \</= 2.

Exclusion Criteria

* History of keratoconjunctivitis, open or closed angle glaucoma, or "dry eye" disease.
* New York Heart Association (NYHA) Grade II or greater congestive heart failure.
* History of myocardial infarction within 6 months prior to Day 1.
* Presence of \>/= Grade 2 peripheral neuropathy.
* Known presence of central nervous system or brain metastases.
* Prior therapy with a conjugated or unconjugated maytansine derivative.

Primary outcomes:
measure: To evaluate safety
timeFrame: ongoing
measure: To determine the maximum-tolerated dose (MTD)
timeFrame: ongoing
Secondary outcomes:
measure: To evaluate pharmacokinetics (PK)
timeFrame: ongoing
measure: To evaluate clinical activity
timeFrame: ongoing
Other outcomes:
Locations:
city: Santa Monica
country: United States
facility: Research Site
state: California
city: Philadelphia
country: United States
facility: Research Site
state: Pennsylvania
city: San Antonio
country: United States
facility: Research Site
state: Texas
Study officials:
References:
Clinical trial NCT03806647: Development and Needs Assessment and Efficiency of Smart Communication System for Patients With ALS (Part 1)
Official title: Taipei Veterans General Hospital
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Amyotrophic Lateral Sclerosis
Keywords: Amyotrophic lateral sclerosis, ALS, communication, needs
Lead sponsor: Taipei Veterans General Hospital, Taiwan
Sponsor class: OTHER_GOV
First posted: 2019-01-16
Enrollment: 20
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Participants with ALS were recruited from ALS clinics(Taipei Veterans General Hospital, Taiwan, R.O.C),20 participants. Participants were eligible for this study if they were diagnosed with definite, probable, probable laboratory-supported, or possible ALS according to the criteria (Brooks et al., 2000).

Brief summary: The research is aimed to explore the needs of clinical patients and their caregiver,so as to provide suggestions to the designer of the communication system.

Detailed description: To promote and develop a smart communication system is helpful to patients with amyotrophic lateral sclerosis (ALS),especially for stage 3 and stage 4 (late stage). Through the needs assessment, the research is aimed to explore the needs of clinical patients and their caregiver,so as to provide suggestions to the designer of the communication system.

Eligibility criteria: Inclusion Criteria:

* Clinical diagnosis of ALS
* Taiwanese and used traditional Chinese(Mandarin).
* If they were older than age 20 years.

Exclusion Criteria:

* Frontotemporal dementia, severe depression, or schizophrenia.
* If they cannot complete the questionnaire with researchers or family members help.

Primary outcomes:
measure: Amyotrophic Lateral Sclerosis Supportive Care Needs (ALSSCN)
timeFrame: 2018.10.01~2020.04.31
Secondary outcomes:
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: Taipei Veterans General Hospital
state: TW
Study officials:
References:
Clinical trial NCT05486247: Molecular Characterization of Gliomas Using a Broad Next Generation Sequencing (NGS)Panel
Official title: Molecular Characterization of Gliomas Using a Broad NGS Panel
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Malignant Glioma
Keywords: Molecular profile
Mutational status
Lead sponsor: Hellenic Cooperative Oncology Group
Sponsor class: OTHER
First posted: 2022-08-03
Enrollment: 32
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with diagnosis of high grade glioma treated in 2 centers of the Hellenic Cooperative Oncology Group (HeCOG).

Brief summary: Gliomas are the most common malignant primary brain tumors with poor prognosis. The genotyping of tumors using NGS platforms enables the identification of genetic alterations that constitute diagnostic, prognostic and predictive biomarkers.Here in, we investigated the molecular profile of 32 tumor samples from 32 patients with high grade gliomas by implementing a broad 80-gene targeted NGS panel while reporting their clinicopathological characteristics and outcomes.


Eligibility criteria: Inclusion Criteria:

Diagnosis of high grade glioma based on tissue biopsy

Exclusion Criteria:

Primary outcomes:
measure: The prevalence of genetic alterations in patients with high grade glioma using a 80 gene NGS panel
timeFrame: April 2019 - December 2021
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT05874947: Accuracy of Different Technologies for Dental Cast Digitization; CBCT Versus Desktop Optical 3D Scanner
Official title: Accuracy of Different Technologies for Dental Cast Digitization; CBCT Versus Desktop Optical 3D Scanner: An Observational Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Evaluate and Compare the Accuracy of Digital Dental Models Generated From Plaster Casts by Two Different Scanning Techniques
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2023-05-25
Enrollment: 24
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Population selected for this study is any healthy male/female participant with complete set of non fractured maxillary or mandibular permanent teeth first molars included.

Brief summary: The objective of this study is to evaluate and compare the accuracy of digital dental models generated from plaster casts by two different scanning techniques including Cone Beam Computed Tomography (CBCT) and extraoral Scanner (EOS) .

The comparison between the two techniques is assessed by orthodontic arch space analysis using linear measurements for arch length and width .


Eligibility criteria: Inclusion Criteria:

* Patients with maxillary or mandibular complete permanent dentition
* Partially edentulous patients provided the dentition are complete from the first molar to the first molar.

Exclusion Criteria:

* Patients with fractured teeth, attrition and/or erosion affecting the anatomical points
* Patients having non-anatomic restorations that may alter cusp anatomy affecting the accuracy of measurements consequently.

Primary outcomes:
measure: Deviation of CBCT and extraoral scanner's measurements from gold standard in arch space analysis.
timeFrame: one year
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Faculty of dentistry ,Cairo University
state: Almanial
Study officials:
References: